Age-Dependent Neurovascular Dysfunction and Damage in a Mouse Model of Cerebral Amyloid Angiopathy

Laibaik Park, PhD; Kenzo Koizumi, MD, PhD; Sleiman El Jamal, MD; Ping Zhou, PhD; Mary Lou Previti, BS; William E. Van Nostrand, PhD; George Carlson, PhD; Costantino Iadecola, MD

Background and Purpose—Accumulation of amyloid-β in cerebral blood vessels occurs in familial and sporadic forms of cerebral amyloid angiopathy and is a prominent feature of Alzheimer disease. However, the functional correlates of the vascular pathology induced by cerebral amyloid angiopathy and the mechanisms involved have not been fully established.

Methods—We used male transgenic mice expressing the Swedish, Iowa, and Dutch mutations of the amyloid precursor protein (Tg-SwDI) to examine the effect of cerebral amyloid angiopathy on cerebrovascular structure and function. Somatosensory cortex cerebral blood flow was monitored by laser-Doppler flowmetry in anesthetized Tg-SwDI mice and wild-type littermates equipped with a cranial window.

Results—Tg-SwDI mice exhibited reductions in cerebral blood flow responses to whisker stimulation, endothelium-dependent vasodilators, or hypercapnia at 3 months when compared with wild-type mice, whereas the response to adenosine was not attenuated. However, at 18 and 24 months, all cerebrovascular responses were markedly reduced. At this time, there was evidence of cerebrovascular amyloid deposition, smooth muscle fragmentation, and pericyte loss. Neocortical superfusion with the free radical scavenger manganic(I-II)meso-tetrakis(4-benzoic acid) porphyrin rescued endothelium-dependent responses and functional hyperemia completely at 3 months but only partially at 18 months.

Conclusions—Tg-SwDI mice exhibit a profound age-dependent cerebrovascular dysfunction, involving multiple regulatory mechanisms. Early in the disease process, oxidative stress is responsible for most of the vascular dysfunction, but with advancing disease structural alterations of the vasomotor apparatus also play a role. Early therapeutic interventions are likely to have the best chance to counteract the deleterious vascular effects of cerebral amyloid angiopathy. (Stroke. 2014;45:000-000.)

Key Words: amyloid-β • cerebral blood flow • cerebrovascular disorder

Cerebral amyloid angiopathy (CAA) is characterized by accumulation of amyloid-β in cerebral arteries, arterioles, and capillaries and is most commonly associated with Alzheimer disease.1-3 CAA can also occur independently of Alzheimer disease, either as a familial form resulting from gene mutations or as a sporadic form observed in the elderly.1,4-7 CAA is associated with damage to the vessels wall, resulting in ischemic or hemorrhagic strokes, microinfarcts, and microhemorrhages.8,9 However, CAA can also alter the regulation of the cerebral circulation leading to vascular insufficiency and increased susceptibility to white matter damage and cognitive impairment.8-11 The mechanisms of these functional alterations and their relationships to the structural damage to cerebral blood vessels remain to be defined.

Transgenic mice (Tg-SwDI), expressing low levels of human amyloid-β precursor protein harboring the Swedish K670N/M671L and vasculotropic Dutch/Iowa E693Q/D694N mutations in neurons, develop extensive cerebral microvascular amyloid deposition especially in cerebral arterioles and capillaries.12 These mice have elevated levels of amyloid-β in brain and exhibit amyloid plaques or amyloid accumulation in blood vessels starting at 6 months.11 The CAA is associated with an age-dependent structural alteration of the cerebral vasculature, neuroinflammation, astrogliosis, and microgliosis.12,13 Cerebrovascular function is also altered in these mice. Thus, the increase in cerebral blood flow (CBF) evoked by neural activity (functional hyperemia), a key mechanism that matches the metabolic needs of active neurons with the delivery of energy substrates via blood flow, and the ability of brain endothelial cells to control CBF are markedly impaired.14 However, because previous studies were conducted in 3-month-old Tg-SwDI mice before amyloid deposition, the relationships linking vascular dysfunction, amyloid accumulation, and vascular damage...
have not been established. Furthermore, the mechanisms of the cerebrovascular dysfunction in Tg-SwDI mice remain to be defined. Growing evidence suggests that amyloid-β exerts its detrimental vascular effects through reactive oxygen species (ROS). However, the contribution of vascular oxidative stress to the cerebrovascular impairments observed in Tg-SwDI mice remains unclear.

Therefore, we sought to investigate the cerebrovascular dysfunction in Tg-SwDI mice and to correlate such dysfunction with the development of vascular damage and with the potential for rescue by ROS scavengers. We found that Tg-SwDI mice exhibit a profound cerebrovascular dysfunction, the magnitude of which is age dependent and is greatest when vascular damage develops. At this age, counteraction of oxidative stress no longer reverses the vascular dysfunction. The findings provide mechanistic insight into the alterations in cerebrovascular regulation induced by CAA and suggest that early intervention is needed to counteract its devastating vascular effects.

Materials and Methods

Mice

All procedures were approved by the Institutional Animal Care and Use Committee of Weill Cornell Medical College. Experiments were performed in Tg-SwDI male mice at 3, 18, and 24 months on a C57BL/6 background. Age-matched C57BL/6 male mice were used as wild-type (WT) controls.

General Surgical Procedures

As described in detail previously, mice were anesthetized with isoflurane (1%-2%), followed by urethane (750 mg/kg, IP) and α-chloralose (50 mg/kg, IP). A femoral artery was cannulated for recording of arterial pressure and collection of blood samples to analyze physiological variables. Arterial blood pressure, blood gases, and rectal temperature were monitored and controlled (Tables I and II in the online-only Data Supplement).

Monitoring of CBF

A small opening was drilled through the parietal bone, the dura was removed, and the site was superfused with a modified Ringer’s solution (37°C; pH 7.3–7.4). Relative CBF was continuously monitored at the site of superfusion with a laser-Doppler flow probe (Vasamedic).

Detection of ROS by Dihydroethidine Fluoromicrography

ROS production was monitored using dihydroethidine (Molecular Probes) fluoromicrography, as previously described. Dihydroethidine (2 μM/L) was topically superfused on the somatosensory cortex for 60 minutes. In some experiments, dihydroethidine was followed by superfusion with the ROS scavenger mangancitrate (MnTBAP) (100 μM/L; Calbiochem) for 30 minutes. At the end of the superfusion, the brain was removed, sectioned (thickness, 20 μm), and processed for detection of ROS-dependent fluorescence. ROS data are expressed as relative fluorescence units.

Measurement of Brain Amyloid-β

Methods for determination of brain amyloid-β levels have been described. Briefly, cerebral hemispheres were sonicated and centrifuged, and amyloid-β(1-40) or amyloid-β(1-42) concentrations (pg/mg) were determined using a sandwich ELISA assay.

Assessment of CAA, Smooth Muscle Fragmentation, and Pericytes

Anesthetized mice were perfused transcardially with heparinized saline, followed by 4% (wt/vol) paraformaldehyde,Brains were removed, postfixed, and sectioned (thickness, 40 μm). Free-floating sections were randomly selected and processed for the labeling as described below. The specificity of the labeling was ensured by omitting the primary antibody or by preabsorption with the antigen. Images were acquired using a confocal laser scanning microscope (Leica) from somatosensory cortex underlying the cranial window (0.38 to 1.94 mm from Bregma). Brain sections from Tg-SwDI and WT mice were processed in a blinded fashion under identical conditions and imaged using identical settings.

For assessment of CAA, brain sections were first incubated with an antibody against the basement membrane marker collagen IV (Col IV; 1:500; rabbit; Abcam) followed by cyanine dye 5–conjugated anti-rabbit secondary IgG (1:200; Jackson ImmunoResearch), and then stained with 0.05% (wt/vol) thioflavin-S and imaged using the appropriate filters.

Quantification of amyloid-β-associated fragmentation of smooth muscle cells is detailed previously. Briefly, brain sections were incubated with an antibody directed against the smooth muscle marker α-actin (1:8000, mouse; Sigma) for 48 hours. After washing, sections were labeled with donkey cyanine dye 5–conjugated anti-mouse IgG (1:200; Jackson ImmunoResearch) and then double-labeled with 0.05% (wt/vol) thioflavin-S. Neocortical arterioles (n=30–50 per group) positive for both amyloid-β and thioflavin-S, ranging in diameter from 20 to 100 μm, were randomly imaged by confocal microscopy (>60). The smooth muscle fragmentation was quantified by counting the number of α-actin fragments of each arteriole using ImageJ and was expressed as the fragmentation index: 100–[(1/number of α-actin fragments)×100].

For pericyte identification, sections were processed for immunofluorescence with anti-rabbit Col IV (1:800; Abcam) and the pericyte marker platelet-derived growth factor receptor-β (10 μg/mL; R&D Systems). Sections were then incubated with donkey fluorescein isothiocyanate–conjugated anti-rabbit and cyanine dye 5–conjugated anti-goat IgG. Images were obtained with a confocal microscope, and platelet-derived growth factor receptor-β+ cell bodies and Col IV+ vessels were counted in random fields using ImageJ and presented as number of Col IV+ vessels or platelet-derived growth factor receptor-β+ cell bodies/mm2.

Experimental Protocol for CBF Experiments

CBF recordings were started after arterial pressure, and blood gases were in a steady state (Tables I and II in the online-only Data Supplement). To study the increase in CBF produced by neural activity, the whiskers were mechanically stimulated for 60 s. The endothelium-dependent vasodilator acetylcholine (10 μM/L; Sigma), bradykinin (50 μM/L; Sigma), and the calcium ionophore A23187 (3 μM/L; Sigma), were superfused over the cortex, and the resulting changes in CBF were monitored. CBF responses to the NO donor S-nitroso-N-acetylpenicillamine (50 μM/L; Sigma), adenosine (400 μM/L; Sigma), or hypercapnia (Pco₂; 50–60 mmHg) were also tested.

In some studies, responses were tested before and 30 minutes after superfusion with Ringer containing vehicle or MnTBAP (100 μM/L).

Data Analysis

Mice treated with MnTBAP were randomly assigned to the vehicle or treatment group. Histological and biochemical analyses were performed in a blinded fashion. Data are expressed as mean±SEM. Two-group comparisons were analyzed by the 2-tailed t test. Multiple comparisons were evaluated by the ANOVA and Tukey test. Differences were considered statistically significant for P<0.05.

Results

Age-Dependent Alterations in Cerebrovascular Function in Tg-SwDI Mice

First, we examined key regulatory responses of the cerebral circulation in WT and Tg-SwDI mice at different ages. In WT
mice, the increase in CBF elicited by neural activity (whisker stimulation) and by the endothelium-dependent vasoactive agents, acetylcholine and bradykinin, but not A23187, were attenuated at 18 and 24 months (Figure 1A and 1B). In contrast, CBF responses evoked by the smooth muscle relaxants adenosine or the NO donor S-nitroso-N-acetylpenicillamine were not significantly attenuated, and the response to hypercapnia was attenuated only at 24 months (Figure 1A and 1B). In Tg-SwDI mice, CBF responses to whisker stimulation, hypercapnia, endothelium-dependent agents, including A23187, and S-nitroso-N-acetylpenicillamine were already reduced at 3 months (Figure 1A–1C). However, the response to adenosine was not attenuated (Figure 1C). With aging (18 and 24 months), cerebrovascular responses were suppressed further in Tg-SwDI mice, and the response to adenosine, which was intact at 3 months, was markedly attenuated (Figure 1C).

Age-Dependent Alterations in Cerebrovascular Structure in Tg-SwDI Mice

Next, we examined the cerebrovascular damage induced by amyloid-β accumulation in Tg-SwDI mice. Brain levels of amyloid-β1–40 and amyloid-β1–42 were already elevated in 3-month-old Tg-SwDI mice (Figure 2A), but there was no amyloid deposition in the somatosensory cortex or its blood vessels, as previously reported.11,14 Amyloid-β levels increased dramatically at 18 and 24 months (Figure 2A), and at 18 months there were abundant amyloid deposits in cerebral arterioles and capillaries (Figure 2B and 2C). Concurrent with the amyloid deposition, microvessels developed a more irregular appearance and smooth muscle cells became fragmented (Figure 2B and 2C). Because pericytes are susceptible to the cytotoxic effects of amyloid-β,20,23,24 we examined their number and morphology using platelet-derived growth factor receptor-β as a marker in the somatosensory cortex. In 3-month-old WT and Tg-SwDI mice, pericytes had a normal appearance and number20 (Figure 3A). However, at 18 months, pericytes were reduced in number and their processes were shorter (Figure 3A–3C). No differences in the number of vascular profiles were observed in WT and Tg-SwDI mice at 18 months when compared with those at 3 months (Figure 3C).

Role of Oxidative Stress in the Cerebrovascular Dysfunction

ROS have been implicated in the cerebrovascular effects of aging and amyloid-β.16,18,21 Therefore, we examined whether ROS production was increased in the brains of Tg-SwDI mice and if so, whether the cerebrovascular dysfunction could be rescued by the treatment with the ROS scavenger MnTBAP. In Tg-SwDI mice, ROS production in somatosensory cortex was higher than that of WT mice, an effect observed both at 3 and at 18 months (Figure 4A). MnTBAP attenuated the ROS-dependent fluorescence both in WT and in Tg-SwDI mice (Figure 4A). However, in WT mice, the cerebrovascular dysfunction was completely reversed by MnTBAP at all ages; but in Tg-SwDI mice, complete rescue was observed only at 3 months (Figure 4B). In 18-month-old Tg-SwDI mice, MnTBAP improved the CBF response to whisker stimulation and acetylcholine but had no statistically significant effect on responses to adenosine and hypercapnia (Figure 4B and 4C).
Discussion

Novel Findings of the Study

The present study describes several novel findings. First, we demonstrated that Tg-SwDI mice, a model of CAA, exhibit age-dependent cerebrovascular dysfunction, which manifest itself first with alterations in neurovascular coupling, hypercapnia, and endothelium-dependent vasodilatation, and then progresses in older mice to a global vasomotor dysfunction involving all responses independently of their mechanism. Second, we found that the global cerebrovascular dysfunction in older Tg-SwDI mice is associated with marked alterations in the vasomotor apparatus, involving damage to smooth muscle cells and loss of pericytes. Third, we demonstrated that the cerebrovascular dysfunction could be rescued by short-term treatment with an ROS scavenger at 3 months, and that these beneficial effects were less evident in older mice, when vascular damage sets in. These observations collectively indicate that, in the absence of CAA, the cerebrovascular dysfunction induced by amyloid-β is fully reversible by countering oxidative stress, except for the response to hypercapnia. With the development of CAA, vascular damage occurs and the dysfunction broadens to involve all the CBF responses studied and is no longer reversible by ROS scavengers.

Exclusion of Potential Sources of Artifacts

The findings of the present study cannot result from differences in the physiological variables of the mice because arterial pressure, blood gases, and body temperature were monitored and did not differ among the groups studied. Differences in the genetic background of the mice are unlikely to play a role in the findings because Tg-SwDI mice were studied longitudinally at different ages, and mice were congeneric with the C57BL/6 background, the strain used as WT control. Furthermore, the rescue of the responses by MnTBAP in 3-month-old Tg-SwDI mice cannot be attributed to a non-specific enhancement of baseline responses because this agent did not affect resting CBF or the magnitude of CBF increases in WT mice.

Tg-SwDI Mice Have a Profound Impairment in Cerebrovascular Function

We found that functional hyperemia, endothelium-dependent responses, and CBF responses to hypercapnia were altered in Tg-SwDI mice starting at 3 months. The involvement of hypercapnia is at variance with the vascular dysfunction observed in 3-month-old Tg2576 mice in which the hypercapnic response is not altered. Although the reasons for this difference remain to be established, the findings suggest...
a broad impairment in the mechanisms of the regulation of the cerebral circulation in Tg-SwDI mice, which is more pronounced than that observed in Tg2576 mice. One possibility is that amyloid-β with the Dutch–Iowa mutations produced by Tg-SwDI is more vasotoxic than WT amyloid-β produced by Tg2576, also leading to alterations of the hypercapnic vasodilatation. Furthermore, it remains to be established whether the dysfunction is related to amyloid-β–induced enhancement of constrictor mechanisms, which may antagonize the effect of the vasodilator stimuli. Additional studies are required to examine these outstanding questions.

It is likely that the attenuation in functional hyperemia and response to acetylcholine is related to a reduction in the bioavailability of NO, which participates in these responses. However, the attenuation of the CBF increase evoked by A23187 and bradykinin cannot be attributed to the lack of NO because these responses are mediated by COX-1. However, the CBF response to adenosine was not affected in 3-month-old Tg-SwDI mice, indicating that the vasomotor function of smooth muscle cells was not affected at this age. However, at 18 and 24 months, the response to adenosine was attenuated, suggesting an impairment of the vasomotor apparatus. This observation is consistent with our neuropathological data, demonstrating loss of smooth muscle cell integrity and pericytes at this age. Therefore, it is likely that damage to these vasomotor cells at 18 and 24 months contributes to the worsening of functional hyperemia and endothelium-dependent responses observed at this age. Because the vascular dysfunction is present also without vascular amyloid accumulation, the data suggest that amyloid-β in soluble form is sufficient to induce vascular dysfunction. However, it would be of interest to correlate the progression of the vascular dysfunction with the development of the vascular pathology in arterioles and capillaries.

Pericytes, intramural vascular cells enriched in capillaries, have recently been implicated in CBF regulation. Our data demonstrating pericyte loss concomitant with a total failure of all vascular responses in aged Tg-SwDI mice are consistent with a role of these cells in cerebrovascular dysfunction. This conclusion is reinforced by the finding that the amyloid accumulation in this model occurs abundantly in capillaries. Pericytes in culture internalize amyloid-β, which may lead to their death, although in Tg-SwDI mice amyloid-β accumulation has been observed in microglia–macrophages but not in pericytes. Both pericyte loss and smooth muscle cell damage could play a role in the vascular dysfunction, but their relative contribution remains to be established.

**ROS Contribution to the Cerebrovascular Dysfunction**

Another major finding of this study is that acute application of the ROS scavenger MnTBAP suppressed ROS production and ameliorated vascular function. However, MnTBAP was most effective in 3-month-old mice, in which MnTBAP completely restored responses to whisker stimulation and acetylcholine. In 18-month-old mice, MnTBAP restored the response only partially. At this time, pronounced alterations in smooth muscle cell structure and pericyte number were observed. These findings suggest that the ability of acute administration of free radical scavengers to counteract the effects of CAA is greatest before the vascular damage sets in. However, we cannot rule out that a more prolonged treatment with MnTBAP or treatment with other agents could be more effective. Premenopausal female mice are resistant to the cerebrovascular dysfunction induced by angiotensin, an effect that depends on the suppression of ROS production by ovarian hormones during the estrous cycle. It remains to be determined whether such protection is observed in premenopausal Tg-SwDI female mice and is lost in the postmenopausal period.

Interestingly, MnTBAP did not rescue the response to hypercapnia even in 3-month-old Tg-SwDI mice. This
observation indicates that ROS do not contribute to the effects of CAA on the response to hypercapnia. Because the vasculature is not damaged at this age, the findings implicate that functional alterations are distinct from those underlying the attenuation of functional hyperemia and endothelium-dependent responses, which were reversed by MnTBAP in this age group. The nature of these mechanisms remains unclear and needs further investigations.

Implications for CAA

Inasmuch as Tg-SwDI mice reflect the human disease, the present findings provide the mechanistic bases for the alterations in CBF regulation reported in patients with CAA. Furthermore, they suggest that the functional alterations induced by CAA are amenable to the treatment in the early stages of the disease process, before structural alterations of cerebral blood vessels occur. At this time, the deleterious vascular effects of amyloid are largely reversible. Unfortunately, current imaging approaches for CAA diagnosis rely on microhemorrhages, reflecting the presence of vascular damage, and early diagnosis of CAA is not yet feasible. A limitation of the CAA model used in the present study is that the pathology is present mainly in microvessels, which is not the case in most patients with sporadic CAA. However, a mitigating factor is that we found a similar ROS-dependent neurovascular dysfunction in aged Tg2576 mice, in which the pattern of vascular amyloid deposition resembles patients with CAA more closely. In that study, we observed that the innate immunity receptor CD36 is involved in the vascular amyloid deposition. It remains to be established whether CD36 has a similar role in Tg-SwDI mice.

Conclusions

We have demonstrated that Tg-SwDI mice, which recapitulate selected features of human CAA, have a profound neurovascular dysfunction that involves not only functional hyperemia and endothelium-dependent responses but also the CBF increase induced by hypercapnia. The dysfunction is age dependent and is greater in older mice, in which profound structural and functional alterations of the cerebrovascular vasomotor apparatus (smooth muscle cells and pericytes) are observed. The ROS scavenger MnTBAP is able to rescue the alterations in functional hyperemia and endothelium-dependent responses in young mice completely, but not in older mice, in which vascular damage has occurred. The findings implicate oxidative stress in the mechanisms of neurovascular dysfunction in Tg-SwDI mice and suggest that treatments for the damaging vascular effects of amyloid are likely to be most effective if instituted early in the course of the disease.

Sources of Funding

This work was supported by National Institutes of Health grants NS37853 (Dr Iadecola), NS052533 (Dr Van Nostrand), and NS41997 (Dr Carlson), by anonymous donor bequest to McLaughlin Research Institute (Dr Carlson), by the Alzheimer Association (Zenith Award to Dr Iadecola) and by the American Heart Association Grant 09SDG2060701 (Dr Park). The continued support of the Feil Family Foundation is gratefully acknowledged.

Disclosures

None.

References

Age-Dependent Neurovascular Dysfunction and Damage in a Mouse Model of Cerebral Amyloid Angiopathy
Laibaik Park, Kenzo Koizumi, Sleiman El Jamal, Ping Zhou, Mary Lou Previti, William E. Van Nostrand, George Carlson and Costantino Iadecola

Stroke. published online April 29, 2014;
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/early/2014/04/29/STROKEAHA.114.005179

Data Supplement (unedited) at:
http://stroke.ahajournals.org/content/suppl/2014/04/29/STROKEAHA.114.005179.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/
## SUPPLEMENTAL MATERIAL

Table SI. Physiological variables of mice examined in figure 1.

<table>
<thead>
<tr>
<th>Genotypes</th>
<th>Age (months)</th>
<th>Stimuli</th>
<th>N</th>
<th>MAP (mmHg)</th>
<th>pCO₂ (mmHg)</th>
<th>pO₂ (mmHg)</th>
<th>pH</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>ACh, Bradykinin, Adenosine</td>
<td>5</td>
<td>81±5</td>
<td>32.9±1.0</td>
<td>129.3±14.3</td>
<td>7.36±0.03</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hypercapnia</td>
<td>5</td>
<td>80±3</td>
<td>57.3±2.1*</td>
<td>132.9±8.5</td>
<td>7.17±0.02*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Whisker, A23187, SNAP</td>
<td>5</td>
<td>84±2</td>
<td>35.0±1.1</td>
<td>127.6±7.2</td>
<td>7.42±0.02</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>ACh, Bradykinin, Adenosine</td>
<td>5</td>
<td>84±2</td>
<td>34.7±1.6</td>
<td>131.8±7.5</td>
<td>7.40±0.04</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hypercapnia</td>
<td>5</td>
<td>86±2</td>
<td>56.9±1.5*</td>
<td>123.1±9.0</td>
<td>7.23±0.03*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Whisker, A23187, SNAP</td>
<td>5</td>
<td>81±5</td>
<td>31.9±2.6</td>
<td>118.9±6.8</td>
<td>7.38±0.03</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hypercapnia</td>
<td>5</td>
<td>81±6</td>
<td>55.4±2.1*</td>
<td>131.0±4.2</td>
<td>7.19±0.01*</td>
</tr>
<tr>
<td>Tg-SwDI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>ACh, Bradykinin, Adenosine</td>
<td>5</td>
<td>83±7</td>
<td>32.4±1.7</td>
<td>126.3±7.6</td>
<td>7.39±0.04</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hypercapnia</td>
<td>5</td>
<td>83±7</td>
<td>56.6±1.3*</td>
<td>130.8±3.4</td>
<td>7.20±0.03*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Whisker, A23187, SNAP</td>
<td>5</td>
<td>75±5</td>
<td>27.1±1.8</td>
<td>136.8±10.9</td>
<td>7.38±0.02</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>ACh, Bradykinin, Adenosine</td>
<td>5</td>
<td>74±5</td>
<td>28.7±1.9</td>
<td>132.9±10.0</td>
<td>7.38±0.03</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hypercapnia</td>
<td>5</td>
<td>73±6</td>
<td>55.2±0.3*</td>
<td>136.6±4.2</td>
<td>7.19±0.01*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Whisker, A23187, SNAP</td>
<td>5</td>
<td>72±7</td>
<td>34.3±2.6</td>
<td>126.0±3.6</td>
<td>7.39±0.04</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>ACh, Bradykinin, Adenosine</td>
<td>5</td>
<td>71±8</td>
<td>35.5±2.3</td>
<td>124.9±8.8</td>
<td>7.38±0.03</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hypercapnia</td>
<td>5</td>
<td>68±8</td>
<td>56.5±4.5*</td>
<td>123.0±4.9</td>
<td>7.14±0.01*</td>
</tr>
</tbody>
</table>

Mean±SEM; *p<0.05 vs normocapnia
<table>
<thead>
<tr>
<th>Genotypes</th>
<th>Treatment</th>
<th>Age (months)</th>
<th>Stimuli</th>
<th>N</th>
<th>MAP (mmHg)</th>
<th>pCO$_2$ (mmHg)</th>
<th>pO$_2$ (mmHg)</th>
<th>pH</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>Vehicle</td>
<td>3</td>
<td>Whisker, A23187, Adenosine</td>
<td>6</td>
<td>84±5</td>
<td>33.9±2.0</td>
<td>131.5±10.0</td>
<td>7.38±0.02</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hypercapnia</td>
<td>6</td>
<td>84±5</td>
<td>55.7±2.0*$</td>
<td>131.4±6.3</td>
<td>7.19±0.03*</td>
</tr>
<tr>
<td></td>
<td>MnTBAP</td>
<td></td>
<td>Whisker, A23187, Adenosine</td>
<td>6</td>
<td>84±4</td>
<td>32.9±1.5</td>
<td>130.9±9.6</td>
<td>7.37±0.02</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hypercapnia</td>
<td>6</td>
<td>83±2</td>
<td>55.2±1.2*$</td>
<td>128.7±9.9</td>
<td>7.20±0.02*</td>
</tr>
<tr>
<td>Tg-SwDI</td>
<td>Vehicle</td>
<td>18</td>
<td>Whisker, A23187, Adenosine</td>
<td>6</td>
<td>81±3</td>
<td>33.7±0.9</td>
<td>133.4±8.1</td>
<td>7.38±0.02</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hypercapnia</td>
<td>6</td>
<td>80±2</td>
<td>56.7±1.2*$</td>
<td>131.5±6.6</td>
<td>7.21±0.01*</td>
</tr>
<tr>
<td></td>
<td>MnTBAP</td>
<td></td>
<td>Whisker, A23187, Adenosine</td>
<td>6</td>
<td>82±1</td>
<td>35.1±1.4</td>
<td>128.1±5.9</td>
<td>7.39±0.03</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hypercapnia</td>
<td>6</td>
<td>82±1</td>
<td>57.6±2.9*$</td>
<td>128.4±5.5</td>
<td>7.22±0.02*</td>
</tr>
</tbody>
</table>

Mean±SEM; *p<0.05 vs normocapnia